A clinical trial to look at how safe different doses of RO7121932 are in people with multiple sclerosis and how the body processes RO7121932

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.

  • Autoimmune Disorder
  • Multiple Sclerosis (MS)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Belgium
  • Canada
  • Germany
  • Israel
  • Italy
  • Moldova
  • Poland
  • Portugal
  • Romania
  • United States
Trial Identifier:

NCT05704361 2020-004122-33 BP42230

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS).

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT05704361,BP42230,2020-004122-33 Trial Identifier
      All Gender
      ≥18 Years & ≤ 65 Years Age
      No Healthy Volunteers

      1. Why is the B-Shuttle clinical trial needed?

      Multiple sclerosis (MS) is a condition where the immune system attacks myelin, the protective layer around nerve fibres. This makes it difficult for the brain to send signals to the rest of the body. Common symptoms include pain, tiredness, vision problems and problems with walking or balance. Most people experience the ‘relapsing-remitting; form of the disease, in which periods of attacks of old or new symptoms, known as ‘relapses’, are followed by times of fewer symptoms, known as “remission”. As opposed to the relapsing-remitting type of MS, people with ‘progressive’ MS have symptoms and disabilities that stay stable for a long time or worsen over time. It is thought that increasing disability in progressive MS is due to nerve damage in the brain.

      Treatments for MS include:

      • Treatment during relapses (usually with steroids)
      • Treatment of symptoms (such as muscle stiffness/spasms, pain, tiredness and depression)
      • The use of disease-modifying therapies (DMTs) to prevent MS relapses and maintain body functions. ‘Relapsing-remitting MS’ may develop into ‘secondary progressive MS’, which is characterised by slowly increasing disability with or without relapses.

      Immune cells that usually protect the body from foreign (or harmful) substances, including bacteria or viruses, can attack nerve cells in people with MS. Treatment with DMTs can reduce disease activity. But a protective barrier around the brain (called the ‘blood-brain barrier’) can make it difficult for medicines like DMTs to pass through and prevent damage to the nerves. Currently, DMTs do not work very well at stopping disability caused by immune cells in the brain both in relapsing and progressive forms of the disease.

      RO7121932 is the clinical trial treatment being tested in this trial – it is an experimental drug (health authorities have not approved it for treating MS) with a ‘brain shuttle technology’ that allows the drug to pass through the blood-brain barrier. Researchers hope that RO7121932 will lower the number of a type of immune cell called ‘B-cells’ in the brain to prevent disability progression in MS. This clinical trial aims to test the safety of RO7121932 at different doses in people living with MS, to understand how well it is tolerated, to measure how the body absorbs, distributes, and gets rid of it and find out what effects, good or bad, RO7121932 has.

      2. How does the B-Shuttle clinical trial work?

      This clinical trial is recruiting people with relapsing as well as primary and secondary progressive forms of MS. People can take part if they are not currently treated with DMTs and they did not have very recent MS activity (assessed via relapses and magnetic resonance imaging [MRI] scans).

      People who take part in this clinical trial (participants) will be given a single dose of the clinical trial treatment RO7121932. They will need to stay in the hospital for up to two nights after being given RO7121932 on Day 1. The clinical trial doctor will see them on Days 1–3, 5, 8, 11, 15, then weekly for 2 weeks, then once a month for 3 months, with a final follow-up visit at 6 months. These hospital visits will include medical checks to see how the participant responds to the treatment and any side effects they may have – some visits/tests may be done by a mobile nurse at the participants’ home if they agree to it. Participants who still have low blood B-cell counts at the follow-up visit will be asked to attend the hospital for monthly blood tests until their B-cell levels are back to normal values. Total time of participation in the clinical trial will be about 8 months. Participants can stop trial treatment and leave the clinical trial at any time.

      3. What are the main endpoints of the B-Shuttle clinical trial?

      The main clinical trial endpoint is the main result measured in the trial. In this clinical trial, the main endpoint is the number and seriousness of any side effects during treatment and the 6-month follow-up period.

      The other clinical trial endpoints include:

      • How the body breaks down, processes and gets rid of RO7121932
      • How RO7121932 affects the immune system

      4. Who can take part in this clinical trial?

      People living with MS can take part in this trial if they are 18–65 years of age (inclusive) and are not being treated with DMTs (people can continue having physiotherapy or taking any treatments for MS symptoms that they have already started).

      People can take part if they have had no recent MS activity – which means they have not had a relapse within 3 months before the start of the trial, have had only one relapse within the past year or have few new or enlarging lesions in the brain on a recent MRI scan. People may not be able to take part in this trial if they cannot walk 5 metres or more with or without aid from devices, have recently received certain treatments such as B-cell therapies, have certain medical conditions other than MS including those affecting the brain or spinal cord, infections, cancer within the last 10 years, or if they are pregnant or breastfeeding, or are planning to become pregnant during the trial.

      5. What treatment will participants be given in this clinical trial?

      Everyone who joins this clinical trial will be given:

      • RO7121932, given once, as an infusion (into the vein)

      If participants have a relapse or their MS becomes active again as shown on MRI scans, they may be offered approved immunotherapy treatment if the study doctor believes this will benefit them. This is an open-label trial, which means that everyone involved, including the participant and the clinical trial doctor, will know the clinical trial treatment the participant has been given.

      6. Are there any risks or benefits in taking part in this clinical trial?

      The safety or effectiveness of the experimental treatment or use may not be fully known at the time of the trial. Most trials involve some risks to the participant. However, it may not be greater than the risks related to routine medical care or the natural progression of MS. People who would like to participate will be told about any risks and benefits of taking part in the clinical trial, as well as any additional procedures, tests, or assessments they will be asked to undergo. All of these will be described in an informed consent document (a document that provides people with the information they need to decide to volunteer for the clinical trial).

      Risks associated with the clinical trial drug
      Participants may have side effects (an unwanted effect of a drug or medical treatment) from the drug used in this clinical trial. Side effects can be mild to severe, even life-threatening, and vary from person to person. Participants will be closely monitored during the clinical trial; safety assessments will be performed regularly.

      RO7121932 has not yet been tested in humans. For this reason, this experimental drug’s side effects are not yet known. Participants will be told about the possible side effects based on laboratory studies or knowledge of similar drugs. RO7121932 will be given as an infusion into a vein (intravenous infusion). Participants will be told about any known side effects of intravenous infusion.

      Potential benefits associated with the clinical trial
      Participants' health may or may not improve from participation in the clinical trial. Still, the information collected may help other people with similar medical conditions in the future.

      Trial Summary

      The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS).

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT05704361,BP42230,2020-004122-33 Trial Identifier
      RO7121932 Treatments
      Multiple Sclerosis Condition
      Official Title

      Official Title: A Multiple-Center, Non-randomized, Open-label, Adaptive, Single-Ascending Dose (Part 1 and Part 2) and Multiple-Ascending Dose (Part 3) Parallel, Phase IB Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 Following Intravenous (Part 1) and Subcutaneous Administration (Parts 2 and 3) in Participants With Multiple Sclerosis

      Eligibility Criteria

      All Gender
      ≥18 Years & ≤ 65 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Expanded Disability Status Scale (EDSS) score ≤7.0 at Screening
      • Participants with relapsing multiple sclerosis (RMS) or progressive multiple sclerosis (PMS) who fulfil international panel criteria for diagnosis (McDonald 2017 criteria)
      • Participants not treated with any approved MS treatment at Screening and not planning to start on any MS therapy during the study (including follow-up)
      • Female participants must practice abstinence or otherwise use contraception
      Exclusion Criteria
      • Evidence of clinical disease activity as defined by any clinical relapse within 3 months prior to screening, or by >1 clinical relapse within 12 months prior to screening
      • Evidence of magnetic resonance imaging (MRI) activity as defined by the presence of ≥ 1 Gadolinium-enhancing T1 lesion in the screening MRI scan or by ≥ 4 new or enlarging T2 lesions in the screening scan as compared to a reference scan
      • Participants who have active progressive multifocal leukoencephalopathy (PML), have had confirmed PML, or have a high degree of suspicion for PML
      • Known presence of other neurological disorders that may mimic MS including but not limited to: neuromyelitis optica spectrum disease, Lyme disease, untreated Vitamin B12 deficiency, neurosarcoidosis, cerebrovascular disorders, and untreated hypothyroidism
      • Known active or uncontrolled bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds, including participants exhibiting symptoms consistent with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within 6 weeks prior to Day 1
      • Participants with a current diagnosis of epilepsy
      • Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal, or other major diseases
      • History of cancer, including hematologic malignancy and solid tumors, within 10 years of screening. Basal or squamous cell carcinoma of the skin that has been excised and is considered cured and in situ carcinoma of the cervix treated with apparent success by curative therapy >1 year prior to screening is not exclusionary
      • Any concomitant disease that may require treatment with systemic corticosteroids or immunosuppressants during course of the study
      • History of currently active primary or secondary (non-drug-related) immunodeficiency
      • History of hypersensitivity to biologic agents or any of the excipients in the formulation
      • Only for cohorts where CSF samples are planned to be collected: Participants with a history of spinal cord compression, raised intra-cerebral pressure, clinically significant vertebral joint pathology or any other current abnormalities in the lumbar region which could prevent the lumbar puncture procedure.

      Prior/Concomitant Therapy:

      • Treatment with any approved MS treatment at Screening. Participants may become eligible after completion of a washout period prior to acquiring any screening laboratory tests but should not be withdrawn from therapies for the sole purpose of meeting eligibility for the trial
      • Previous treatment with RO7121932, alemtuzumab, cladribine, mitoxantrone, cyclophosphamide, total body irradiation, bone marrow transplantation, and hematopoietic stem cell transplantation. For the USA only, previous treatment with daclizumab
      • Previous treatment with anti-CD20 B-cell-depleting therapies (e.g., rituximab, ocrelizumab, or ofatumumab)
      • <12 months prior to acquiring any screening laboratory tests, * ≥12 months prior to acquiring any screening laboratory tests, if B-cells are outside the normal range, or not back to individual baseline ± 20% (if data are available), * If discontinuation of a prior B-cell depletion therapy was motivated by safety reasons
      • Current or prior treatment with natalizumab (if <24 months prior to acquiring any screening laboratory tests)

      Prior/Concurrent Clinical Study Experience:

      • Participation in an investigational drug medicinal product or medical device study within 30 days before Screening or within five times the pharmacodynamic (PD) or pharmacokinetic (PK) half-life (if known), whichever is longer

      Diagnostic Assessments:

      • Positive result on human immunodeficiency virus (HIV1) and HIV2, hepatitis C, or hepatitis B
      • Participants with suicidal ideation or behavior within 6 months prior to Screening or participants who, in the Investigator's judgment, pose a suicidal or homicidal risk
      • Vaccination with a live or live-attenuated vaccine within 6 weeks prior to Day 1

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now